Skip To Main Content
Stephanie Baum on Muck Rack

Stephanie Baum

Philadelphia
As seen in: MedCity News, MSN, Flipboard, Phys.org, Medical Xpress, MedPage Today, TechOhio, Above the Law, EIN News, Tech Xplore, NewsBreak and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Stephanie

Contact Stephanie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

INVEST Digital Health Conference Returns with Focus on Consumers

|
By Stephanie Baum
| MedCity News Verified
Although direct to consumer business models have had mixed success in healthcare historically, a report from Boston Consulting Group published earlier this year noted that some key guidelines have emerged in terms of how the healthcare industry now thinks about consumers. They include designing products and services that address friction for patients with empathy; improving trust with transparency and accountability; and adoption of a consumer-first mindset.
Open in Who Shared Issue with article?

Debunked Episode 29: CMS GLP-1 Drug Pilot Program, RPM Strategy Raise Questions

|
By Stephanie Baum
| MedCity News Verified
Two developments at Centers for Medicare and Medicaid Services (CMS) captured the attention of Debunked Podcast co-hosts on the latest episode. Arundhati Parmar, editor-in-chief of MedCity News, noted that a new pilot Bridge program to help Medicare beneficiaries lose weight using popular GLP-1 drugs carries a hefty price tag of $741 million per month after the $50 monthly beneficiary copay, if all eligible recipients take part in the program.
Open in Who Shared Issue with article?

Cannabinoid pathways may offer targets for kidney disease as CKD affects 850 million people

|
By Stephanie Baum
| MSN Verified
Approximately 850 million people globally (9.1% of the world's population) have chronic kidney disease (CKD). The number of affected individuals has grown steadily during the past 20 years and is on track to continue rising. Existing drugs, such as RAAS inhibitors and angiotensin receptor blockers, are commonly prescribed, but their effectiveness varies from patient to patient. Moreover, these drugs can slow disease progression but cannot stop it.
Open in Who Shared View Duplicates (2) Issue with article?
See all 9,261 licensed articles (9,262 Total)